Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Gains from Sales and Divestitures (2017 - 2025)

Altimmune (ALT) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $267903.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 6.99% to $267903.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $267903.0, a 6.99% decrease, with the full-year FY2024 number at $288977.0, up 151.25% from a year prior.
  • Gains from Sales and Divestitures was $267903.0 for Q3 2025 at Altimmune, down from $288977.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $288977.0 in Q4 2024 to a low of $44778.0 in Q2 2022.
  • A 4-year average of $161094.4 and a median of $107830.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 189.73% in 2024, then fell 6.99% in 2025.
  • Altimmune's Gains from Sales and Divestitures stood at $74000.0 in 2022, then soared by 55.43% to $115018.0 in 2023, then surged by 151.25% to $288977.0 in 2024, then decreased by 7.29% to $267903.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Gains from Sales and Divestitures are $267903.0 (Q3 2025), $288977.0 (Q4 2024), and $288040.0 (Q3 2024).